As of Oct 02
| +0.31 / +0.79%|
The 10 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 44.00, with a high estimate of 62.00 and a low estimate of 31.00. The median estimate represents a +11.14% increase from the last price of 39.59.
The current consensus among 12 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.